Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials

被引:27
作者
Amini, B. [1 ]
Beaman, C. B. [6 ]
Madewell, J. E. [1 ]
Allen, P. K. [2 ]
Rhines, L. D. [3 ]
Tatsui, C. E. [3 ]
Tannir, N. M. [4 ]
Li, J. [5 ]
Brown, P. D. [5 ]
Ghia, A. J. [5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, 1400 Pressler St,Unit 1475, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[6] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
关键词
COMPUTED-TOMOGRAPHY; RADIOTHERAPY; MRI;
D O I
10.3174/ajnr.A4528
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: Osseous pseudoprogression on MR imaging can mimic true progression in lesions treated with spine stereotactic radiosurgery. Our aim was to describe the prevalence and time course of osseous pseudoprogression to assist radiologists in the assessment of patients after spine stereotactic radiosurgery. MATERIALS AND METHODS: A secondary analysis of 2 prospective trials was performed. MRIs before and after spine stereotactic radiosurgery were assessed for response. Osseous pseudoprogression was defined as transient growth in signal abnormality centered at the lesion with a sustained decline on follow-up MR imaging that was not attributable to chemotherapy. RESULTS: From the initial set of 223 patients, 37 lesions in 36 patients met the inclusion criteria and were selected for secondary analysis. Five of the 37 lesions (14%) demonstrated osseous pseudoprogression, and 9 demonstrated progressive disease. There was a significant association between single-fraction therapy and the development of osseous pseudoprogression (P = .01), and there was a significant difference in osseous pseudoprogression-free survival between single- and multifraction regimens (P = .005). In lesions demonstrating osseous pseudoprogression, time-to-peak size occurred between 9.7 and 24.4 weeks after spine stereotactic radiosurgery (mean, 13.9 weeks; 95% CI, 8.6-19.1 weeks). The peak lesion size was between 4 and 10 mm larger than baseline. Most lesions returned to baseline size between 23 and 52.4 weeks following spine stereotactic radiosurgery. CONCLUSIONS: Progression on MR imaging performed between 3 and 6 months following spine stereotactic radiosurgery should be treated with caution because osseous pseudoprogression may be seen in more than one-third of these lesions. Single-fraction spine stereotactic radiosurgery may be associated with osseous pseudoprogression. The possibility of osseous pseudoprogression should be incorporated into the prospective criteria for assessment of local control following spine stereotactic radiosurgery.
引用
收藏
页码:387 / 392
页数:6
相关论文
共 12 条
  • [1] Bakardjiev AI, 1996, CANCER, V78, P864
  • [2] Phase I clinical evaluation of near-simultaneous computed tomographic image-guided stereotactic body radiotherapy for spinal metastases
    Chang, EL
    Shiu, AS
    Lii, MF
    Rhines, LD
    Mendel, E
    Mahajan, A
    Weinberg, JS
    Mathews, LA
    Brown, BW
    Maor, MH
    Cox, JD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05): : 1288 - 1294
  • [3] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    Choi, Haesun
    Charnsangavej, Chuslip
    Faria, Silvana C.
    Macapinlac, Homer A.
    Burgess, Michael A.
    Patel, Shreyaskumar R.
    Chen, Lei L.
    Podoloff, Donald A.
    Benjamin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1753 - 1759
  • [4] Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer
    Dahele, Max
    Palma, David
    Lagerwaard, Frank
    Slotman, Ben
    Senan, Suresh
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (07) : 1221 - 1228
  • [5] Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
    de Wit, MCY
    de Bruin, HG
    Eijkenboom, W
    Smitt, PAES
    van den Bent, MJ
    [J]. NEUROLOGY, 2004, 63 (03) : 535 - 537
  • [6] Tumor pseudoprogression following radiosurgery for vestibular schwannoma
    Hayhurst, Caroline
    Zadeh, Gelareh
    [J]. NEURO-ONCOLOGY, 2012, 14 (01) : 87 - 92
  • [7] Radiographic changes after lung stereotactic ablative radiotherapy (SABR) - Can we distinguish recurrence from fibrosis? A systematic review of the literature
    Huang, Kitty
    Dahele, Max
    Senan, Suresh
    Guckenberger, Matthias
    Rodrigues, George B.
    Ward, Aaron
    Boldt, R. Gabriel
    Palma, David A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2012, 102 (03) : 335 - 342
  • [8] KNOSPE WH, 1966, BLOOD-J HEMATOL, V28, P398
  • [9] Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
    Prager, A. J.
    Martinez, N.
    Beal, K.
    Omuro, A.
    Zhang, Z.
    Young, R. J.
    [J]. AMERICAN JOURNAL OF NEURORADIOLOGY, 2015, 36 (05) : 877 - 885
  • [10] Near simultaneous computed tomography image-guided stereotactic spinal radiotherapy: An emerging paradigm for achieving true stereotaxy
    Shiu, AS
    Chang, EL
    Ye, JS
    Lii, MF
    Rhines, LD
    Mendel, E
    Weinberg, J
    Singh, S
    Maor, MH
    Mohan, R
    Cox, JD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03): : 605 - 613